MetaShape Pharma to Present MS001 Data at MedInvest and RESI

MetaShape Pharma will share new preclinical data and development updates for MS001 at two September investor conferences in New York and Boston. The company says the oral GLP-1 co-therapy is designed to boost fat loss by increasing energy expenditure while preserving muscle mass.

Why it matters: - MetaShape Pharma is trying to position MS001 as a complementary obesity treatment, not a replacement for GLP-1 drugs. - The company is targeting a gap in current weight-loss care: improving the durability and quality of weight loss while preserving lean muscle mass. - MetaShape is also preparing a US$20 million Series A to move MS001 toward clinical proof of concept.

What happened: - MetaShape Pharma AG said it will present new preclinical data and strategic updates for MS001 at two investor events in September 2026. - Randall Riggs, MetaShape’s chief executive officer, will attend the Fall 2026 MedInvest Biotech & Pharma Investor Conference on September 15–16 in New York City. - Riggs is scheduled to present on September 15 at 10:40 a.m. EST and meet with investors and potential strategic partners during the conference. - Shanta Bantia, PhD, MetaShape’s co-founder and chief scientific officer, will participate virtually in RESI Boston 2026 on September 25 and 28–29. - MetaShape will use both events to discuss MS001, its latest preclinical findings and its development strategy.

The details: - MS001, also called ulodesine hemiglutarate, is an oral inhibitor of purine nucleoside phosphorylase in pre-IND development. - MetaShape describes MS001 as a first-in-class metabolic amplifier designed to enhance the efficacy and durability of GLP-1 therapies for obesity. - The company says GLP-1 therapies mainly reduce appetite and energy intake, while MS001 is designed to increase energy expenditure. - MS001 is being developed to activate thermogenic pathways in adipose tissue and promote fat-selective weight loss without additional caloric restriction. - MetaShape says the program is intended to preserve lean muscle mass and address weight regain after GLP-1 discontinuation. - The company also says the approach could help reduce gastrointestinal burden and may extend weight-loss efficacy in people with higher adiposity. - MS001 is a patent-pending salt form of ulodesine, a PNP inhibitor that has been administered to more than 500 subjects in clinical studies and has generally been shown to be safe and well tolerated. - MetaShape says that prior human exposure to ulodesine provides relevant safety data for development in obesity and cardiometabolic disorders. - MedInvest expects more than 125 investors and 50 presenting companies, along with keynote and panel sessions and programs involving the National Institutes of Health. - RESI is designed to connect early-stage life sciences companies with investors and strategic partners through targeted one-on-one meetings.

Between the lines: - MetaShape is pitching MS001 as a “both sides of the energy-balance equation” play, pairing appetite suppression from GLP-1 drugs with higher energy expenditure. - That framing matters because current obesity drugs can work well on weight loss but still leave questions around muscle preservation, discontinuation effects and long-term durability. - Riggs said the new preclinical data further strengthen the case for MS001 as a differentiated GLP-1 co-therapy and position the program for its next stage of clinical and strategic development.

What's next: - MetaShape will present at MedInvest on September 15 and meet with investors and potential partners across the two-day event. - The company will hold virtual meetings during RESI Boston on September 25 and 28–29. - MetaShape said it is preparing a Series A financing of US$20 million to advance MS001 through clinical proof of concept. - The company expects initial efficacy data in 2029.

The bottom line: - MetaShape is using two September investor conferences to advance MS001 as a GLP-1 co-therapy aimed at better fat loss, better muscle preservation and longer-lasting weight-loss results. - MetaShape Pharma on LinkedIn